New combo therapy aims to keep lung cancer from returning after surgery

NCT ID NCT06624059

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 32 times

Summary

This study tests the safety of combining the targeted drug alectinib with chemotherapy after surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). Eleven patients who had their tumor completely removed will receive up to four cycles of the combination. The goal is to see if this approach is safe and helps control the disease long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, 05505, South Korea
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

Perugia, Umbria, 06156, Italy
Beijing Cancer Hospital

Beijing, 100142, China
Guangdong General Hospital

Guangzhou, 510000, China
Instituto do Cancer do Estado de Sao Paulo - ICESP

São Paulo, São Paulo, 01246-000, Brazil
Jinhua municipal central hospital

Jinhua, China
RedSalud Vitacura

Santiago, Chile
Royal North Shore Hospital

St Leonards, New South Wales, 2065, Australia
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
The third people's hospital of Chengdu

Chengdu, China
Yunnan Cancer Hospital

Kunming, 650118, China

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER